Peptides Anti-Aging & LongevityRecovery & Healing Preclinical (animal) data

Cartalax

4.1 hours

Half-life

0.5–2 mg

Typical dose

10–20 days per course, repeated 2–3× yearly (reported)

Cycle length

Peptide bioregulator researched for cartilage and joint tissue support.

Key takeaways

Synthetic cartilage-targeted tripeptide (Ala-Glu-Asp) from the Khavinson bioregulator program.
Evidence is cell-culture and animal work from one research group; no randomized human trials.
Plotter values are estimates modeled on similar short peptides, not measured human PK.
Reported courses run 10–20 days; all dosing is anecdotal, nothing is established in humans.

🚧 Expanded guide coming soon. This compound has PK data and a source — a full overview, mechanism, and dosing guide is pending editorial review.

Reported dosing protocols

Protocols reported in research literature and clinic/community use — informational context, not a dosing recommendation.

Use case	Dose	Route	Frequency	Duration
Cartilage / joint support (community)	1–2 mg	SubQ; oral capsules also sold	Once daily	10–20 days, repeated 2–3× yearly

Pharmacokinetic summary

Model tier: Simple (t½ + F, Tmax estimated)
Half-life: 4.1 hours
Bioavailability: 40%
Typical dose: 0.5–2 mg

Frequently asked questions

Can Cartalax regrow cartilage?

There's no human evidence it can. The literature is cartilage cell-culture and stem-cell gene-expression work from the originating research group, plus animal studies. No randomized trial has shown cartilage repair or reduced joint symptoms in people.

Is Cartalax safe?

No formal human safety trials exist. Short peptides are generally assumed low-toxicity, but with research-grade material the practical risks are purity and sterility, which a certificate of analysis only partly addresses.

How does Cartalax differ from other cytogen peptides?

Each cytogen is a different short sequence aimed at a different tissue: Cartalax (AED) targets cartilage, Cortagen (AEDP) nervous tissue, Vesugen (KED) blood vessels. They share the same unproven gene-regulation rationale and the same evidence gaps.

References

Estimated (bioregulator) — Cartilage-targeted peptide bioregulator; human PK not established.
Khavinson & Popovich, Molecules 2021 — Peptide Regulation of Gene Expression: A Systematic Review — Maps Cartalax (AED) to cartilage gene regulation; summarizes the Khavinson short-peptide literature.
Khavinson & Linkova, Int J Mol Sci 2022 — Transport of ultrashort peptides via POT and LAT carriers — In-vitro transport study confirming Cartalax's AED sequence and peptide-carrier interactions.

Comments

Loading comments…